Fig 2: Leukocyte cell-derived chemotaxin 2 promoted THP-1 monocyte chemotaxis. A: Chemotactic effects of Lect2 on THP-1 cells when treated with different doses; B: Comparison of chemotactic effects between Lect2 and MCP-1. The data represent the mean ± SD. aP < 0.05; bP < 0.01. ctrl: Control.

Fig 3: The effect of leukocyte cell-derived chemotaxin 2 on immune cell infiltration in the concanavalin A-induced acute liver injury model. A-E: Quantitative changes in the infiltration of various immune cells in the livers of wild-type and Lect2-KO mice, with or without concanavalin A (ConA) treatment; F: Representative images of infiltrated immune cells in ConA-treated wild-type and Lect2-KO mice, with or without ConA treatment. The data represent the mean ± SD. aP < 0.05; bP < 0.01; cP < 0.001; dP < 0.0001. ns: Not significant; Scale bar: 50 μm.

Fig 4: Lect2-KO mice showed less severe liver injuries. A and B: The levels of serum alanine transaminase (ALT) and aspartate transaminase (AST) in the wild-type and Lect2-KO mice, with or without carbon tetrachloride treatment; C and D: The levels of serum ALT and AST in the wild-type and Lect2-KO mice, with or without concanavalin A treatment. The data represent the mean ± SD. aP < 0.05; bP < 0.01. ns: Not significant; ALT: Alanine transaminase; AST: Aspartate transaminase.

Fig 5: The expression of leukocyte cell-derived chemotaxin 2 was increased in acute liver injury models. A: The relative expression of Lect2 mRNA in the liver tissues of carbon tetrachloride (CCl4)-treated wild-type mice; B The levels of serum leukocyte cell-derived chemotaxin 2 (LECT2) in CCl4-treated wild-type mice; C: The relative expression of Lect2 mRNA in the liver tissues of concanavalin A (ConA)-treated wild-type mice; D: The levels of serum LECT2 in ConA-treated wild-type mice. The data represent the mean ± SD. ctrl: Control; ns: Not significant; aP < 0.05; bP < 0.01; cP < 0.001; dP < 0.0001. ctrl: Control; ns: Not significant; LECT2: Leukocyte cell-derived chemotaxin 2.